Holen Sie sich die Stockscreener-App
5.10
0.00%
0.00
Handel nachbörslich:
5.20
0.10
+1.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.10
Offen:
$5.05
24-Stunden-Volumen:
4.29M
Relative Volume:
1.01
Marktkapitalisierung:
$1.56B
Einnahmen:
$248.37M
Nettoeinkommen (Verlust:
$11.74M
KGV:
102.00
EPS:
0.05
Netto-Cashflow:
$18.24M
1W Leistung:
-9.73%
1M Leistung:
-8.44%
6M Leistung:
+10.15%
1J Leistung:
-22.02%
1-Tages-Spanne:
$5.02
$5.15
1-Wochen-Bereich:
$4.79
$5.72
52-Wochen-Spanne:
$3.3812
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Vergleichen Sie MNKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.10 | 1.50B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
FDA accepts application for MannKind inhaled insulin in kids - MassDevice
How MannKind Corporation stock responds to policy changesJuly 2025 Spike Watch & Safe Entry Point Identification - newser.com
MannKind (MNKD) Seeks FDA Approval for Afrezza in Younger Patien - GuruFocus
Is MannKind Corporation stock poised for growth2025 Technical Overview & Stepwise Swing Trade Plans - newser.com
MannKind (MNKD) Advances Inhaled Insulin for Pediatric Diabetes - GuruFocus
FDA accepts MannKind’s application for inhaled insulin in children - Investing.com
MannKind Corporation Submits Supplemental Biologics License Application for Needle-Free Afrezza Inhalation Powder for Pediatric Diabetes Treatment - Quiver Quantitative
Real time scanner hits for MannKind Corporation explainedMarket Trend Review & Free Reliable Trade Execution Plans - newser.com
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes - Stock Titan
HC Wainwright & Co. Reiterates Buy Rating for MNKD with $11 PT | MNKD Stock News - GuruFocus
MannKind Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
MannKind (NASDAQ:MNKD) Given "Hold (C)" Rating at Weiss Ratings - MarketBeat
Using data models to predict MannKind Corporation stock movement2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
MannKind completes acquisition of scPharmaceuticals in $296.5 million deal - Investing.com
Risk adjusted return profile for MannKind Corporation analyzedWeekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
Heatmap analysis for MannKind Corporation and competitorsJuly 2025 Spike Watch & Verified Swing Trading Watchlist - newser.com
How moving averages guide MannKind Corporation tradingWatch List & Weekly Momentum Picks - newser.com
MannKind (NASDAQ:MNKD) Upgraded at Zacks Research - MarketBeat
MannKind completes acquisition of scPharmaceuticals By Investing.com - Investing.com Canada
MannKind completes acquisition of scPharmaceuticals; SCPH to be delisted from Nasdaq - Investing.com
MannKind (MNKD) Completes Acquisition of scPharmaceuticals to Bo - GuruFocus
MannKind completes acquisition of scPharmaceuticals - Investing.com
MannKind Corporation Completes Acquisition of scPharmaceuticals Inc. to Enhance Revenue Growth and Expand Cardiometabolic Therapy Portfolio - Quiver Quantitative
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care - Yahoo Finance
>$370M annualized run rate: MannKind completes scPharmaceuticals acquisition, adds FUROSCIX - Stock Titan
A Fresh Look at MannKind (MNKD) Valuation Following Leadership Change with New Chief Medical Officer - simplywall.st
Does MannKind (NASDAQ:MNKD) Deserve A Spot On Your Watchlist? - Yahoo Finance
Why MannKind Corporation (NNFN) stock is trending on social mediaEarnings Summary Report & Safe Capital Growth Stock Tips - newser.com
How Dr. Ajay Ahuja’s Appointment at MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
Assessing MannKind’s Share Price After FDA Clears Pediatric Use for Afrezza in 2025 - simplywall.st
Key metrics from MannKind Corporation’s quarterly dataRate Cut & Community Trade Idea Sharing - newser.com
Published on: 2025-10-02 20:45:52 - newser.com
Revolution Medicines hires Mirati, ALX vet Sandler - biocentury.com
MannKind Gets A Price Bump As Pipeline Progresses - Finimize
Is MannKind Corporation (NNFN) stock undervalued historicallyMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Is MannKind Corporation a good long term investmentSector ETF Performance & Take Advantage of Momentum Stocks - earlytimes.in
MannKind (MNKD) Appoints New Chief Medical Officer - GuruFocus
MNKD Appoints New Chief Medical Officer to Strengthen Leadership Team - GuruFocus
MannKind appoints Ajay Ahuja as chief medical officer - Investing.com
MannKind Corporation Appoints Dr. Ajay Ahuja as Chief Medical Officer - Quiver Quantitative
Former Global Medical Head at Allergan: Dr. Ajay Ahuja Joins MannKind as Chief Medical Officer - Stock Titan
Will MannKind Corporation (NNFN) stock see insider accumulationJuly 2025 Rallies & Stock Timing and Entry Methods - newser.com
Will a bounce in MannKind Corporation offer an exitEarnings Overview Summary & Community Verified Swing Trade Signals - newser.com
Non Tuberculous Mycobacterial Infections Market Dynamics - openPR.com
MannKind (NASDAQ:MNKD) Shares Down 5%Time to Sell? - MarketBeat
MannKind (NASDAQ:MNKD) Earns Buy Rating from HC Wainwright - MarketBeat
Should you hold or exit MannKind Corporation nowWeekly Stock Recap & Scalable Portfolio Growth Ideas - newser.com
Price action breakdown for MannKind CorporationQuarterly Profit Report & Free Technical Confirmation Trade Alerts - newser.com
MannKind Corporation (NASDAQ:MNKD) Sees Significant Drop in Short Interest - MarketBeat
Insider Selling: MannKind (NASDAQ:MNKD) Insider Sells 47,000 Shares of Stock - MarketBeat
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):